Investment Summary

DefiniGEN provides human cells to the drug discovery sector for use in lead optimisation and toxicity programmes. DefiniGEN’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology